Trevi Therapeutics, Inc. Amortization of Debt Issuance Costs and Discounts
Trevi Therapeutics, Inc. (TRVI) reported Amortization of Debt Issuance Costs and Discounts of $180.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-18.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2025-03-18
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-06-30 was $99.00K, a 30.77% decline year-over-year.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for the quarter ending 2023-03-31 was $81.00K, a 47.40% decline year-over-year.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $180.00K, a 65.38% decline from fiscal 2022.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $520.00K, a 13.19% decline from fiscal 2021.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2021 was $599.00K, a 163.88% increase from fiscal 2020.
- Trevi Therapeutics, Inc. amortization of debt issuance costs and discounts for fiscal 2020 was $227.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $0.00 derived: sum of 2 quarters · filed 2025-03-18 | $99.00K derived: sum of 3 quarters · filed 2025-03-18 | $180.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $99.00K derived: sum of 2 quarters · filed 2024-11-06 | $180.00K 10-Q · filed 2024-11-06 | $281.00K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $180.00K 10-Q · filed 2024-08-08 | $281.00K derived: sum of 3 quarters · filed 2024-08-08 | $403.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $81.00K 10-Q · filed 2024-05-07 | $182.00K derived: sum of 2 quarters · filed 2024-05-07 | $304.00K derived: sum of 3 quarters · filed 2024-05-07 | $447.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $223.00K derived: sum of 2 quarters · filed 2024-03-20 | $366.00K derived: sum of 3 quarters · filed 2024-03-20 | $520.00K 10-K · filed 2024-03-20 |
| 2022-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $265.00K derived: sum of 2 quarters · filed 2023-11-09 | $419.00K 10-Q · filed 2023-11-09 | $576.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $143.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $297.00K 10-Q · filed 2023-08-10 | $454.00K derived: sum of 3 quarters · filed 2023-08-10 | $605.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $154.00K 10-Q · filed 2023-05-11 | $311.00K derived: sum of 2 quarters · filed 2023-05-11 | $462.00K derived: sum of 3 quarters · filed 2023-05-11 | $608.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $308.00K derived: sum of 2 quarters · filed 2023-03-16 | $454.00K derived: sum of 3 quarters · filed 2023-03-16 | $599.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $297.00K derived: sum of 2 quarters · filed 2022-11-10 | $442.00K 10-Q · filed 2022-11-10 | $601.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $291.00K 10-Q · filed 2022-08-11 | $450.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $145.00K 10-Q · filed 2022-05-12 | $304.00K derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $227.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $68.00K 10-Q · filed 2021-11-10 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $0.00 derived: sum of 2 quarters · filed 2020-03-16 | $17.00K derived: sum of 3 quarters · filed 2020-03-16 | $60.00K 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $17.00K derived: sum of 2 quarters · filed 2019-11-14 | $60.00K 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $17.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $60.00K 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | $43.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |